Rein Therapeutics, Inc.
No enriched coverage for $RNTX in the last 7 days.
No SEC Form 4 filings for $RNTX in the last 30 days.
See all $RNTX insider activity →Rein Therapeutics, Inc. (RNTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K NASDAQ false 0001420565 0001420565 2026-07-20 2026-07-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July
Rein Therapeutics (NASDAQ: RNTX) said it has expanded its Phase 2 RENEW trial of inhaled peptide LTI-03 for idiopathic pulmonary fibrosis into the United Kingdom, with the first U.K. patient randomized. The company reported 16 patients enrolled to date. Trial sites are enrolling in the U.S., Australia, and the U.K., with two additional countries expected to add sites soon.
VON RICKENBACH JOSEF H purchased 47,060 shares of Rein Therapeutics, Inc. (RNTX) at an average of $1.05 ($1.04–$1.07) across 4 trades over 2026-05-21 to 2026-05-27.
Recent RNTX coverage spans financial news, corporate actions and market movers.
The disclosed vote results confirm governance actions (board seats, share authorization expansion) but do not provide new operating or financial guidance.
U.K. site activation and continued enrollment expansion reduce execution risk for the Phase 2 program and may support near-term sentiment for RNTX’s LTI-03 timeline.
This is a small-to-moderate insider buy that may support near-term sentiment, but it is not a fundamental catalyst by itself.
Rein Therapeutics stock is experiencing a notable surge in trading volume, likely due to recent news or developments. The increased volume suggests heightened trader interest, but the stock's price movement remains uncertain without additional technical or fundamental data.
RNTX exhibits a somewhat bullish sentiment, which could be reinforced by positive biotech news, but the direct impact of Rein Therapeutics' FDA clearance is limited.
alphai scores every news story that mentions RNTX with an AI model for sentiment and relevance, and aggregates insider trades from Rein Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rein Therapeutics, Inc. (RNTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K NASDAQ false 0001420565 0001420565 2026-07-20 2026-07-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July
2 min readRein Therapeutics (NASDAQ: RNTX) said it has expanded its Phase 2 RENEW trial of inhaled peptide LTI-03 for idiopathic pulmonary fibrosis into the United Kingdom, with the first U.K. patient randomized. The company reported 16 patients enrolled to date. Trial sites are enrolling in the U.S., Australia, and the U.K., with two additional countries expected to add sites soon.
4 min readVON RICKENBACH JOSEF H purchased 47,060 shares of Rein Therapeutics, Inc. (RNTX) at an average of $1.05 ($1.04–$1.07) across 4 trades over 2026-05-21 to 2026-05-27.
1 min readRein Therapeutics ( NASDAQ:RNTX ) stock is trading higher on Monday, with a session volume of 41.2 million compared to its average volume of 162.67 thousand, according to data from Benzinga Pro. What Happened: The U.S.
2 min readRein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of ...
2 min readPeer-reviewed publication highlights potential breakthrough anti-fibrotic properties of LTI-03 in lung tissue from IPF patients ...
3 min readAUSTIN, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Rein Therapeutics ( "Rein" ) ( NASDAQ: RNTX ) , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the UK ...
3 min readAUSTIN, Texas, Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Rein Therapeutics ( "Rein" ) RNTX, a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that Chief Scientific ...
2 min readRein Therapeutics to present at IPF Summit ...
2 min read
